Levosert One (Levonorgestrel)

Levonorgestrel released from the intrauterine system acts locally on the cervix, endometrium and tubal epithelium. It thickens cervical mucus, reduces sperm motility, suppresses endometrial growth, and may inhibit ovulation, thereby preventing fertilisation and implantation of a fertilised egg.

The dose is predetermined by the device’s design; each Levosert One unit contains a specific amount of levonorgestrel that is released at a low, steady rate for up to five years. The prescribing clinician selects the appropriate device based on the patient’s clinical needs.

Levosert One is not intended for use during an existing pregnancy and must be inserted only after confirming the patient is not pregnant. Women who become pregnant after insertion should consult their healthcare provider. Breastfeeding is generally considered compatible, but the prescriber should evaluate individual risk‑benefit factors.

To order Levosert One, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levosert One, like other levonorgestrel IUS devices, offers hormone‑based contraception with reduced menstrual bleeding, whereas copper IUDs provide non‑hormonal contraception but may increase bleeding. Compared with similar levonorgestrel systems, Levosert One delivers comparable efficacy and duration, with a comparable safety profile.

Levosert One should be stored at room temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures until it is ready for insertion by a qualified healthcare professional.

Levosert One is inserted into the uterine cavity by a trained clinician during an outpatient procedure. The device is placed through the cervical canal using a specialised inserter, after confirming the patient is not pregnant and that the uterine cavity is suitable for placement.

Serious but uncommon risks include uterine perforation during insertion, pelvic inflammatory infection, and ectopic pregnancy if contraceptive failure occurs. Patients should be advised to seek immediate medical attention for severe abdominal pain, fever, abnormal bleeding or signs of infection.

Levosert One is contraindicated in women with a current pregnancy, active pelvic infection, known or suspected uterine anomalies that could impede placement, a history of breast cancer, or unexplained vaginal bleeding. It should also be avoided in patients with severe liver disease or those taking medications that markedly reduce levonorgestrel effectiveness.